A recent UC San Diego study suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may significantly improve outcomes for colon cancer patients. Researchers analyzed data from over 6,800 patients, finding those taking GLP-1 medications had less than half the five-year mortality rate compared to those not on the drugs. This protective effect remained even after accounting for various health factors, with a more pronounced benefit in patients with high BMIs. While the exact mechanisms are still under investigation, the results point to potential anti-cancer benefits beyond the drugs’ known effects on blood sugar, inflammation, and weight.
Read More
Health officials are investigating a potential link between weight loss and diabetes injections (GLP-1 medicines) and an increase in reports of acute pancreatitis. The Medicines and Healthcare products Regulatory Agency (MHRA) has received nearly 400 reports of acute pancreatitis associated with medications like Mounjaro, Wegovy, Ozempic, and liraglutide, with nearly half involving Mounjaro. Due to the severity of the disease and increased usage of these medicines, the MHRA is launching a study, including genetic testing, to explore potential factors. Both the MHRA and drug manufacturers emphasize the importance of reporting adverse events and the need for healthcare professionals to monitor patients closely.
Read More
The FDA approved Novo Nordisk’s Ozempic to treat chronic kidney disease in patients with Type 2 diabetes, expanding its use beyond diabetes management. This approval allows Ozempic to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in this patient population. A late-stage trial demonstrated Ozempic significantly reduced severe kidney outcomes by 24%, slowed kidney function decline, and lowered cardiovascular event risk. The approval highlights the broader health benefits of GLP-1 drugs, impacting treatment for comorbid conditions frequently found together.
Read More
John Q. Hosedrinker